Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma

British Journal of Clinical Pharmacology

Volumn 41, Issue 2, 1996, Pages 160-162

  Watkins, W M ^a,b,c   Mungai, M ^a   Muhia, D K ^c   Mberu, E K ^c   Gathua, S ^d   Winstanley, P A ^b   Gilks, C F ^a,e   Nunn, P ^a,f  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^d KENYATTA NATIONAL HOSPITAL   (Kenya)

^e LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug reaction; HIV infection; Pharmacokinetics; Thiacetazone

Indexed keywords

ISONIAZID; THIAZINA; THIOACETAZONE;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MIXTURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; STEADY STATE; TUBERCULOSIS;

EID: 0030044821     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00175.x     Document Type: Article

References (14)

1. Nunn P, Porter J, Winstanley P. Thiacetazone - avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993; 87: 578-582.
2. Nunn P, Gicheha C, Hayes R, et al. Cross-sectional survey of HIV infection among patients with tuberculosis in Nairobi, Kenya. Tubercle and Lung Disease 1991; 73: 45-51.
3. Nunn PP, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thiacetazone in HIV-seropositive patients treated for tuberculosis. Lancet 1991; 337: 627-630.
4. Munthali MM, Warndorff DK, Koka CW, Glynn JR, Salaniponi FLM. Thiacetazone reactions [letter]. Trans R Soc Trop Med Hyg 1995; 89: 238.
5. World Health Organisation. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thiacetazone. Wkly Epidemiol Rec 1992; 67: 1-3.
6. Mertens A, Bunge R. The present status of the chemotherapy of tuberculosis with Conteben, a substance of the thiosemicarbazone series. Am Rev Tub 1950; 61: 20-35.
7. Hinshaw HC, McDermott W. Thiosemicarbazone therapy of tuberculosis in humans. Am Rev Tub 1950; 61: 145-157.
8. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-395.
9. Pearson CA. Dosage of thiacetazone [letter]. Lancet 1992; 339: 553.
10. Fox W. Advances in the treatment of respiratory tuberculosis. Practitioner 1970; 205: 502.
11. Jenner PJ, Ellard GA, Swai OB. A study of thiacetazone blood levels and urinary excretion in man using high performance liquid chromatography. Lepr Rev 1984; 55: 121-128.
12. Evengard B, Von Sydow M, Ehrnst A, Pehrson PO, Lundbergh P, Lindre E. Filter paper sampling of blood infected with HIV: effect of heat on antibody activity and viral infectivity. Br Med J 1988; 297: 1178.
13. Ritschel WA. Handbook of basic pharmacokinetics, 3rd edition. Hamilton, Ontario: Drug Intelligence Publications, pp. 269-281.
14. Sen P, Chatterjee R, Saha J, Roy H. Thiacetazone concentration in blood related to grouping of tubercular patients, its treatment, results and toxicity. Ind J Med Res 1974; 62: 557-564.